Skip to main content
SpringerLink
Log in

Influenza Virus Sialidase and Structure-Based Drug Design

  • Chapter
  • First Online:
Influenza Virus Sialidase - A Drug Discovery Target

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Structure-based drug design was critical in the development of the currently available drugs for treating influenza virus infection. Recent reports show there are in fact two different groups of influenza virus A sialidases, with the main structural difference between the two groups being a flexible loop region in the vicinity of the active site. This report looks at how the crystal structures of the new group 1 sialidases have been used to design new influenza virus A sialidase inhibitors which would target the flexible loop region. Although there have been several studies using molecular dynamics and docking techniques, to date there has been only one report of inhibitors that have been designed, synthesised and proved to target the flexible loop region.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Numbering used throughout reflects that reported for influenza A virus N2 sialidase.

References

  1. Klenk HD (2011) Influenza virus virology. In: von Itzstein M (ed) Influenza virus sialidase: a drug discovery target. Springer, Heidelberg

    Google Scholar 

  2. Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41–44

    Article  PubMed  CAS  Google Scholar 

  3. Varghese JN, Laver WG, Colman PM (1983) Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303:35–40

    Article  PubMed  CAS  Google Scholar 

  4. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327–332

    Article  PubMed  CAS  Google Scholar 

  5. Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM (1993) Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol 232:1069–1083

    Article  PubMed  CAS  Google Scholar 

  6. Burmeister WP, Henrissat B, Bosso C, Cusack S, Ruigrok RW (1993) Influenza B virus neuraminidase can synthesize its own inhibitor. Structure 1:19–26

    Article  PubMed  CAS  Google Scholar 

  7. Colman PM (2009) New antivirals and drug resistance. Annu Rev Biochem 78:95–118

    Article  PubMed  CAS  Google Scholar 

  8. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45–49

    Article  PubMed  CAS  Google Scholar 

  9. Smith FI, Palese P (1989) Variation in the influenza virus genes: epidemiological, pathogenic and evolutionary consequences. In: Krug RM (ed) The influenza virus. Plenum, New York, pp 319–350

    Google Scholar 

  10. Colman PM (1994) Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687–1696

    Article  PubMed  CAS  Google Scholar 

  11. Laver G, Garman E (2002) Pandemic influenza: its origin and control. Microbes Infect 4:1309–1316

    Article  PubMed  Google Scholar 

  12. Colman PM (1994) Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687–1696

    Article  PubMed  CAS  Google Scholar 

  13. Laver G, Garman E (2002) Pandemic influenza: its origin and control. Microbes Infect 4:1309–1316

    Article  PubMed  Google Scholar 

  14. Chan J, Bennet AJ (2011) Enzymology of influenza virus sialidase. In: von Itzstein M (ed) Influenza virus sialidase: a drug discovery target. Springer, Heidelberg

    Google Scholar 

  15. Thomson R, von Itzstein M (2011) The development of carbohydrate-based influenza virus sialidase inhibitors. In: von Itzstein M (ed) Influenza virus sialidase: a drug discovery target. Springer, Heidelberg

    Google Scholar 

  16. Streicher H, Stanley M (2011) The development of non-carbohydrate-based influenza virus sialidase inhibitors. In: von Itzstein M (ed) Influenza virus sialidase: a drug discovery target. Springer, Heidelberg

    Google Scholar 

  17. Xu XJ, Zhu XY, Dwek RA, Stevens J, Wilson IA (2008) Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 82:10493–10501

    Article  PubMed  CAS  Google Scholar 

  18. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D et al (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17:1266–1268

    Article  PubMed  CAS  Google Scholar 

  19. Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, Russell RJ, van der Werf S, Thomson RJ, Naffakh N, von Itzstein M (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 1:113

    Article  PubMed  Google Scholar 

  20. von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967–974

    Article  Google Scholar 

  21. von Itzstein M, Thomson R (2009) Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol 189:111–154

    Article  Google Scholar 

  22. Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403–3408

    Article  PubMed  CAS  Google Scholar 

  23. Collins PJ, Haire LF, Lin YP, Liu JF, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258–U1261

    Article  PubMed  CAS  Google Scholar 

  24. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA (2008) Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem 51:3878–3894

    Article  PubMed  CAS  Google Scholar 

  25. Park JW, Jo WH (2010) Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Eur J Med Chem 45:536–541

    Article  PubMed  CAS  Google Scholar 

  26. Wang YT, Chan CH, Su ZY, Chen CL (2010) Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase. Biophys Chem 147:74–80

    Article  PubMed  CAS  Google Scholar 

  27. Durrant JD, McCammon JA (2010) Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. Comput Biol Chem 34:97–105

    Article  PubMed  CAS  Google Scholar 

  28. Wen WH, Wang SY, Tsai KC, Cheng YSE, Yang AS, Fang JM, Wong CH (2010) Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 18:4074–4084

    Article  PubMed  CAS  Google Scholar 

  29. Sun JY, Cai SX, Yan N, Mei H (2010) Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Eur J Med Chem 45:1008–1014

    Article  PubMed  CAS  Google Scholar 

  30. Chen CY, Huang HJ, Tsai FJ, Chen CYC (2010) Drug design for Influenza A virus subtype H1N1. J Taiwan Inst Chem Eng 41:8–15

    Article  CAS  Google Scholar 

  31. Li Y, Zhou BC, Wang RX (2009) Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. J Mol Graph Model 28:203–219

    Article  PubMed  Google Scholar 

  32. D'Souza C, Kanyalkar M, Joshi M, Coutinho E, Srivastava S (2009) Search for novel neuraminidase inhibitors: design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods. Biochim Biophys Acta-Biomembr 1788:1740–1751

    Article  Google Scholar 

  33. An JH, Lee DCW, Law AHY, Yang CLH, Poon LLM, Lau ASY, Jones SJM (2009) A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. J Med Chem 52:2667–2672

    Article  PubMed  CAS  Google Scholar 

  34. Rungrotmongkol T, Frecer V, De-Eknamkul W, Hannongbua S, Miertus S (2009) Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res 82:51–58

    Article  PubMed  CAS  Google Scholar 

  35. Mitrasinovic PM (2009) On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys Chem 140:35–38

    Article  PubMed  CAS  Google Scholar 

  36. Garcia-Sosa AT, Sild S, Maran U (2008) Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model 48:2074–2080

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, QLD, 4222, Australia

    Jeffrey C. Dyason & Mark von Itzstein

Authors
  1. Jeffrey C. Dyason
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark von Itzstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark von Itzstein .

Editor information

Editors and Affiliations

  1. Gold Coast Campus, Inst. Glycomics, Griffith University, Parklands Drive, Southport, 4215, Queensland, Australia

    Mark von Itzstein

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Basel AG

About this chapter

Cite this chapter

Dyason, J.C., von Itzstein, M. (2012). Influenza Virus Sialidase and Structure-Based Drug Design. In: von Itzstein, M. (eds) Influenza Virus Sialidase - A Drug Discovery Target. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-7643-8927-7_4

Download citation

Publish with us

Policies and ethics

Search

Navigation